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Background: High-concentration-capsaicin-patches (Qutenza®) have been put on the market as a treatment for
peripheral neuropathic pain. A minimum infrastructure and a determinate skill set for its application are required.
Our aim was to assess the feasibility of treatment with high-concentration-capsaicin-patches in clinical practice in a
variety of refractory peripheral neuropathic pain syndromes in non-diabetic patients.
Methods: Observational, prospective, single-center study of patients attended to in the Pain Unit of a tertiary
hospital, ≥18 year-old non-responders to multimodal analgesia of both genders. The feasibility for the application
of capsaicin patch in clinical practice was evaluated by means of the number of patients controlled per day when
this one was applied and by means of the times used for patch application.
Results: Between October 2010 and September 2011, 20 consecutive non-diabetic patients (7 males, 13 females)
with different diagnoses of refractory peripheral neuropathic pain syndromes, with a median (range) age of 60 (33–88)
years-old were treated with a single patch application. The median (range) number of patients monitored per day was
not modified when the capsaicin patch was applied [27 (26–29)] in comparison with it was not applied [28 (26–30)].
The median (range) total time to determine and mark the painful area was 9 (6–15) minutes and of patch application
was 60 (58–65) minutes. No important adverse reactions were observed.
Conclusion: High-concentration-capsaicin-patch treatment was feasible in our unit for the treatment of a population
with refractory peripheral neuropathic pain. The routine of our unit was not affected by its use.
Keywords: Peripheral neuropathic pain, Capsaicin patch, Clinical practiceBackground
Neuropathic pain management often involves the use of
many therapeutic approaches (anti-epileptics, opioids,
tricyclic antidepressants as well as noradrenaline and
serotonin re-uptake inhibitors) that are not free of side ef-
fects [1-7]. In 2010, a new treatment (high-concentration* Correspondence: magimene@clinic.ub.es
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reproduction in any medium, provided the orcapsaicin patches, Qutenza®) for non-diabetic peripheral
neuropathic pain in adults was put on the market. It was
available in our hospital from October of that same year.
High-concentration capsaicin patches should be ap-
plied by a physician or by a health care professional
under the supervision of a physician. Furthermore, spe-
cific skills and procedures should be applied according
to the summary of the product [8]. They include as pre-
treating the area with a topical anesthetic prior to its ap-
plication to reduce application related discomfort. This
implies that solely applying the capsaicin patch requiresentral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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addition, within the context of the economic crisis, know-
ing whether this treatment can be conducted successfully
in our facilities and what it implies may aid us in deciding
if it should be included as an analgesic in our hospital.
Therefore, the aim of this study was to assess the feasi-
bility of the capsaicin patch applied in a pain unit of a
tertiary hospital for peripheral neuropathic pain in non-
diabetic patients who are non-responders to multimodal
analgesia. Data on the tolerability, safety and effective-
ness was also gathered.
Methods
Study design
This was an observational, prospective, single-center
study of patients treated with the capsaicin patch in the
Pain Unit. This study was based on the clinical practice
without any modification. That is, the patients were ad-
ministered the patches regardless of whether the study
taking place. Therefore, this study simply took the op-
portunity to study their effects. This study was per-
formed according to the stipulations of the Declaration
of Helsinki and the level of protection of confidentiality
concerning the protection of personal data as required
by Spanish laws (LOPD 15/1999) was ensured. All pa-
tients gave their written informed consent for their
medical information to be used for purposes of scien-
tific research in accordance with the ethical committee
of the participating site (Hospital Clinic de Barcelona).
The Ethical Committee approved the informed consent
in September 2010.
The capsaicin patch was applied following the instruc-
tions of the summary of product characteristics [8]. More-
over, blood pressure was measured with pressure cuffs
(Critikon, GE Healthcare United kingdom, SA), every
10 minutes, from 15 minutes before applying the patch
until 30 minutes after removing the patch and an electro-
cardiogram register was performed before and after patch
application.
Study population
Patients included in this study had to fulfill the following
eligibility criteria: men or women, ≥18 years old with
peripheral neuropathic pain, non-responders to multi-
modal analgesia and candidates to be treated with the
capsaicin patch. No minimum VAS was required for in-
clusion. Patients with hypersensitivity to the active sub-
stance or to any of the excipients were not included.
The following data were gathered: age, sex, diagnosis,
previous analgesic treatments, pain intensity, localization
and area of pain, concomitant pain medication, indica-
tors of feasibility, health state and adverse events related
to the capsaicin patch as well as the effectiveness of the
capsaicin patch.Feasibility for the application of capsaicin patch in
clinical practice
The indicators used to assess the feasibility in clinical
practice were “number of patients visited per day when
the patch was applied” and “number of patients visited
the same day of the previous week if the patch was not
applied in the Pain Unit”. Likewise, as indicator of feasi-
bility was used the times for patch application: “time to
determine and mark the painful area”, “time of patch ap-
plication” and “time to monitor”.
The “number of the patients visited per day when
the patch was applied” was defined as the total num-
ber of patients visited in the Pain Unit the day that
capsaicin patch was applied and corrected by the
number of doctors who attended patients that day.
The “number the patients visited the same day of the
previous week if the patch was not applied in the Pain
Unit” was defined as the number of patients attended to
in the Pain Unit the same day of the previous week that
the capsaicin patch was applied and corrected by the
number of doctors who attended patients that day. The
previous week was chosen whenever no patient was
treated with capsaicin patch.
“Time to determine and mark the painful area” on the
skin was defined as the total time (in minutes) needed by
the physician to determine and mark the painful area. This
variable includes: hair removal, washing and drying the
skin, topical anaesthetic pretreatment and cutting the
patch to match the size and shape of the treatment area.
“Time of patch application” was defined as the total time
(in minutes) from when the patch was applied until it was
removed. “Time to monitor” was defined as the total time
in minutes of monitored blood pressure from when the
patient laid down on the couch until he/she was dis-
charged from the unit.
Tolerability and effectiveness
The tolerability and safety of capsaicin patch (adverse
events related to capsaicin patch application, electrocar-
diogram and blood pressure during treatment applica-
tion) was gathered. Likewise, the pain intensity and its
evolution (at 2 and 12 weeks after the treatment) was
evaluated by means of a Numerical Rating Pain Scale
(NRPS, ‘0’ for no pain during the last 24 hours, and ‘10’
for the worst possible pain during the last 24 hours) at
baseline (before applying the capsaicin patch treatment)
and 12 weeks later (last visit). Furthermore, the pain in-
tensity was also gathered by means of a verbal NRPS
through a telephone control 2 weeks after applying the
capsaicin patch. Likewise, the neuropathic pain was di-
agnosed by the validated Spanish versions of the DN4
with a score equal to or above 4 and by the Brief Pain
Inventory (BPI). The health state was measured by
means of the validated Spanish version of the EuroQol-
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later. Concomitant pain medications during the 12-week
study were recorded.
Statistical analysis
No formal sample size was performed. The sample size
was defined as the whole population treated with the
capsaicin patch in the first year available in our hospital.
A descriptive analysis was performed to describe base-
line population characteristics. Continuous variables were
described as median (range: minimum-maximum) and
categorical data were summarized as absolute frequency
and percentages. As an exploratory analysis, the primary
variable: the number of patients monitored per day in the
Pain Unit when the capsaicin patch was or when was not
applied was compared. The median and mean percentage
changes in NPRS scores from baseline to 2 and 12 weeks
later were calculated. The treatment success (responder)
of the capsaicin patch was defined as a reduction of
greater than 30% in pain intensity at 12 weeks from base-
line. The percentage of responders and its corresponding
95% confidence intervals (95% CI) were calculated. The
correlation between pain intensity evolution and health
state was assessed. Data was recorded and analyzed using
Microsoft Excel running on Windows XP (Redmont, CA).
Results
Patient characteristics
A total of 20 consecutive patients (7 men and 13 women),
who fulfilled the inclusion and exclusion criteria, were
treated with the high-concentration capsaicin patch be-
tween October 2010 and September 2011 (both included)
in its first year of availability in our hospital. All these pa-
tients were included in this study and all of them gave their
consent. The median (range) age was 60 (33–88) years-old.
The median (range) of the history of pain treated with the
patch was of 4 (0.6-14) years. The baseline characteristics
of each patient included is shown in Table 1.
Prior to applying the capsaicin patch treatment, the
diagnosis of peripheral neuropathic pain in non-diabetic
patients was confirmed: post-herpetic neuralgia (6 pa-
tients), total knee arthroplasty post-surgical pain (3), pain-
ful scar (4: axilla, foot, shoulder and post-nephrectomy),
femoral cutaneous neuropathy (2: in one patient with
medical history of big hematoma in the leg), neuroma (3),
complex regional pain syndrome (CRPS)-I after Colles’
fracture (1) and HIV-associated neuropathy 1). The me-
dian (range) DN4 score was 6 (4–10).
All patients included had been treated with multimodal
analgesia (including interventional techniques in some
cases). Previous multimodal analgesia is shown in Table 1.
The concomitant analgesic treatments during the 12 week
study were unchanged, that is, neither the doses nor the
posology was increased.Feasibility for the application of capsaicin patch in
clinical practice
The capsaicin patch was applied to 20 consecutive pa-
tients without problems who were candidates for treat-
ment (applicability 100%).
The median number of patients monitored per day
was not modified when the capsaicin patch was applied
[27 (26–29)] in comparison with when the capsaicin
patch was not applied [28 (26–30)]. The frequency for
patients treated with the capsaicin patch was more or
less every 2 weeks and only 2 patients were treated in
the same week on only one occasion. Only in one case
two patient were treated in two consecutive weeks and
in the same day of the week, being the reference day the
two same days of the previous week (two different
weeks) when capsaicin was not applied.
The median (range) total time to determine, mark the
painful area and apply local anesthetic was 9 [6-15] mi-
nutes. The median (range) total time of patch applica-
tion was 60 (58–65) minutes. The median (range) time
of blood pressure monitoring (“time to monitor”) was
105 (99–109) minutes: 15 (14–18) minutes before apply-




Pain during the capsaicin patch application (15 patients)
was the most frequently reported adverse event. The pain
intensity (NRPS) scored between 1 and 3. Only six (30%)
patients required the administration of oral NSAIDs. Ery-
thema on the area where the capsaicin patch was applied
was reported in 9 (45%) patients, and ice was administered
to 4 (20%) patients to reduce the sensation of heat. Prur-
itus was reported in 1 (5%) patient.
No alteration in the electrocardiogram register after cap-
saicin patch application was found. A slight increase in
blood pressure (median of 4 mmHg in mean arterial pres-
sure) was observed in the first fifteen minutes of capsaicin
patch application. This increment in blood pressure was
neither statistically nor clinically significant.
Effectiveness of the capsaicin patch
All patients were pre-treated with a topical anesthetic
cream (EMLA, Astrazeneca Farmaceutica Spain, S.A.)
prior to application of a high-concentration capsaicin
patch to reduce application related discomfort. The body
areas treated were: thorax (7 patients), knee (3), thigh
external side (2), leg external side (1), groin (1), foot (2),
left flank (1), finger (2) and wrist (1).
The median (range) pain intensity at baseline was 8 (4–
9) [mean (sd): 7.5 (1.7)] and it was 7 (0–9) [mean (sd): 5.8
(2.6)] at 12 weeks from the capsaicin patch treatment. The
overall median (range) percentage of the reduction in pain
Table 1 Baseline characteristics of all patients included (n = 20)
Pain background (years)a DN4 Previous analgesic treatments Concomitant analgesic treatments
during 12 weeks study








2 7 Anticonvulsants, Opioids, TL,
antidepressants and IT
Anticonvulsants
24 4 Anticonvulsants TL, and IT Anticonvulsants, Opioids
and antidepressant
5 8 Opioids, TL, LIc and IT No treatment
6 5 Opioids, TL, NSAIDs, anticonvulsants and IT Opioids and anticonvulsants
Total knee arthroplasty
post-surgical pain
4 6 TL, NSAIDs, anticonvulsants and IT Antidepressant and Opioids
2 5 Opioids, TL, anticonvulsants and IT Opioids and antidepressants
4 6 LI, NSAIDs and IT Opioids anticonvulsants and TL
Painful scar 0.6 6 Opioids, TL, anticonvulsants and IT Opioids, TL and anticonvulsants
3 9 TL and Opioids TL and NSAIDs
2 9 Opioids, TL, NSAIDs and anticonvulsants Opioids and anticonvulsants
4 9 Opioids, anticonvulsants and IT Opioids, anticonvulsants, and TL
Femoral cutaneous neuropathy 14 9 TL, NSAIDs and IT TL
6 9 Opioids and anticonvulsants Antidepressant
Neuroma 5 9 TL and IT No treatment
5 9 Anticonvulsants TL, and IT Anticonvulsants and NSAIDs
10 9 NSAIDs, anticonvulsants , IT, LI No treatment
CRPS-I 1 9 TL and IT Anticonvulsants and antidepressants
HIV-associated neuropathy 5 9 Anticonvulsants Opioids, TL,
and antidepressants
Anticonvulsants
CRPS-I: complex regional pain syndrome type I.
aPain background: time (years) of pain related to the process studied.
bTopical lidocaine.
cLidocaine infusion.
dInterventional technique: neuroaxial blocks, intercostals blocks and sympathetic blocks.
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(32)]. Eight (40%, 95% CI: 19%-64%) out of 20 treated pa-
tients were considered responders (≥30% of reduction
from baseline): 4 (57%) out of 7 men and 4 (31%) out of
13 women. In the group of responder patients, the median
(range) percentage of the reduction in NPRS pain scores
was 56% (38%-100%) [mean (sd): 62.1 (21–0)], and in
non-responders 11% (−17%, 25%) [mean (sd): 3.2
(13.6)]. Based on the responder definition of a pain re-
duction ≥50% from baseline, 5 (25%, 95% CI: 9%-49%)
out of 20 patients treated with a high-concentration
capsaicin patch [1 (14%) man and 4 (31%) women] were
achieved a pain reduction ≥50% from baseline (Table 2).
Figure 1 shows the percentage of responders for periph-
eral neuropathic pain diagnosis. It is worth noting that
only 4 patients (20%) did not previously receive an
interventional treatment. Of those four patients, 2 pa-
tients were capsaicin patch responders. The evolution
of pain is depicted in Figure 2.Concomitant pain medications during the 12 weeks of
study are summarized in Table 1. No new medication
was started during the 12 weeks of study. The patients
carried on with the medication administered prior to
capsaicin patch treatment because they presumably were
on optimal doses.
The median (range) health state (EuroQol VAS) at base-
line was 50 (20–90) [mean (sd): 50.8 (22.0)], and the de-
scriptive system scored is shown in Table 1. The health
state at 12 weeks was 50 (20–100) [mean (sd): 55.3 (25.0)].
Six patients (30%) had a EuroQoL VAS equal to or greater
than 70, suggesting a good quality of life. In the group of
responders, the EuroQol VAS at 12 weeks was a median
(range) 80 (50–100) [mean (sd): 77.5 (19.2)] and it was 40
(20–80) [mean (sd): 44.2 (20.2)] in the no responder
group; and the median (range) of change (baseline minus
at 12 weeks) in the EuroQol VAS was of 12.5 (−20, 50)
[mean (sd): 16.9 (23.7)] in responders and of 10 [−70, 30]
in non-responders [mean (sd): 0.4 (27.3)].
Table 2 Health state evolution based on EuroQol-5D
Health state (EuroQol-5D)
Baseline At 12 weeks Difference
Descriptive VASa VASa
Post-herpetic neuralgia 11121 60 75 +15
22233 25 50 +25
22232 50 40 −10
11131 30 80 +50
22232 25 40 +15
12222 70 50 −20
Total knee arthroplasty
post-surgical pain
22232 90 20 −70
21121 50 60 +10
22333 30 40 +10
Painful scar 22333 20 30 +10
11132 90 90 0
21333 35 20 +15
22232 20 20 0
Femoral cutaneous
neuropathy
11231 80 90 +10
11232 50 80 +30
Neuroma 21222 70 80 +10
12232 70 40 −30
11231 50 100 +50
CRPS-I 11323 50 50 0
HIV-associated
neuropathy
21221 50 70 +20
aVisual Analogue Scale (VAS) of EuroQol-5D.
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This observational, prospective 12-week study reports
novel data on the feasibility (single 60-minute topical ap-
plication) of the high-concentration capsaicin patch in
patients who did not respond to multimodal analgesia.
One of the most important reasons for performing this
feasibility study was to identify both real and potentialFigure 1 Responders to the capsaicin patch treatment by
peripheral neuropathic pain diagnosis [PH: post-herpetic neuralgia
(n: 6); TKA: total knee arthroplasty post-surgical pain (n: 3); PS:
painful scar (n:4); NFC: Femoral cutaneous neuropathy (n: 2); N:
neuroma (n: 3); CRPS-I: complex regional pain syndrome type I
(n: 1); HIV: HIV-associated neuropathy (n: 1)].problems that may be encountered in applying this new
treatment (capsaicin patch) routinely in the clinical prac-
tice. Our pain unit has three treatment rooms, three
consultations rooms, and we work altogether with two
specialized pain nurses leading to a flexible work minim-
izing the negative impact of the treatment application.
During the consultation clinic the physician could develop
the normal activity because the nurses were trained in per-
forming this procedure including the patient monitoring.
It is remarkable that no more than one patient was
treated with a capsaicin patch per day and it was only in
1 week that the capsaicin patch treatment was applied to
two patients. The aforementioned along with the small
sample size may affect the interpretation of the feasibil-
ity data. However, the results suggest that the use of
high-concentration capsaicin patch in our pain unit of a
tertiary hospital may not have a relevant organizational
impact insofar as the burden of visited patients was not
affected the work-force. Thus, it can be carried out as
planned within the estimated times.
The use of high-concentration capsaicin patches requires
organization [8-10]. This study has allowed us, besides de-
termining the potential impact that the treatment might
have on our routine, to determine the adequacy of facilities
and equipment that are presently available and how much
real time is required to manage this treatment. The use of
this treatment required a space where the treatment could
be applied and the patient could be somewhat comfortable
during the application. In addition, a nurse specialized in
pain treatment is required for nearly 2 hours to apply the
capsaicin patch, whose tasks are rescheduled to be per-
formed during certain phases of the procedure, also a
physician must be available at the facility.
In spite of the time required to manage this treatment,
capsaicin patch application time did not affect the number
of patients treated per day in our Pain Unit. The capsaicin
patch was not a difficult treatment to manage and it might
be an alternative in patients with peripheral neuropathic
pain and multimodal analgesia non-responders.
Another objective of this feasibility study was to con-
vince us of the treatment’s value. Conclusions on the ef-
fectiveness of capsaicin patch could not be drawn due to
the study design, the low number of patients included and
to the variability of indications of peripheral neuropathic
pain tested. To our knowledge, limited or no evidence
based on clinical trials is available on the efficacy of the
capsaicin patch for peripheral neuropathic pain different
from post-herpetic neuralgia and HIV-associated neur-
opathy in non-diabetic patients [11,12] or in diabetic poly-
neuropathy [7,12]. As expected, the group of patients
diagnosed with post-herpetic neuralgia had a mean reduc-
tion of pain with respect to baseline similar to that re-
ported in the registration clinical trials [13]. Likewise, if all
patients treated with high-concentration capsaicin patch
Figure 2 Evolution of pain according with responders and non-responders.
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also the expected. It is remarkable that 6 responder pa-
tients had been treated with interventional techniques
with no relief of pain before capsaicin patch. A possible
explanation would be that the action of anesthetics on
depolarization is limited in time. In contrast, capsaicin
causes a defunctionalization which could last up weeks
until recovery [14-16]. On the other hand, no interven-
tional technique was performed on 2 responder patients,
which represent 25% of responder patients. This could
open a possibility for the capsaicin patch to be a thera-
peutic alternative in patients that have not received inter-
ventional treatment. Nevertheless, clinical trials of efficacy
are required to answer this interesting question. Nonethe-
less, the reduction of pain seems to be associated with a
health state improvement. The patients with a higher basal
quality of life (>70 VAS of EQ) are better responders. The
descriptive analysis performed might suggest that the pro-
file of responders might be related to the absence ofproblems with walking about, problems with self-care,
no problems with the performance of usual activities
and to a state of moderate anxiety or depression at the
moment of capsaicin patch application. Likewise, the
patients that responded to the capsaicin patch improved
their quality of life.
The capsaicin patch was well tolerated. As expected, the
most commonly reported adverse reactions were local tran-
sient pain at the application site, erythema and pruritus.
At this point, it is worth mentioning that in our patients
topical anaesthetic pretreatment was only applied for a
time less than 60 minutes as specified in the Summary of
Product Characteristics. In no case was it necessary to re-
move the patch before time. To manage the acute pain
during the application of the capsaicin patch, oral analge-
sics (NSAIDs) and local cooling (ice) were administered in
30% and 20% of the patients, respectively. In fact, short-
acting opioids, as recommended in the summary of prod-
uct characteristics, were not necessary.
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before drawing any conclusion. The study design (obser-
vational and without control group) is not ideal for
evaluating the impact of the capsaicin patch in clinical
practice or for evaluating efficacy. The small sample size
could lead to underestimating or overestimating the re-
sults obtained. In fact, this study was planned as ex-
ploratory. Data concerning the time of the analgesic
treatment before inclusion in the study was not col-
lected, and this might be affected the effectiveness. The
evolution of pain was only based on 3 controls (at base-
line, at 2 weeks and at 12 weeks). In this vein, when the
study was planned, it was thought that the moment of
pain intensity control (between 8:00 am to 3:00 pm)
could not be standardized. In order to minimize the ef-
fect of variability at the moment of gathering the pain
intensity, this one was based on the worst pain in the
last 24 hours. Likewise, in our pain unit, the interven-
tional procedures are performed twice a week in the op-
erating theatre but on different days from capsaicin
patch application. Hence, the feasibility results may not
be applicable in hospitals with different organizational
structure.
Conclusions
Data from this study provides evidence that the high-
concentration capsaicin patch treatment was feasible in
the pain unit of a tertiary hospital for the treatment of a
variety of refractory peripheral neuropathic pain syn-
dromes in a population of non-diabetic patients. The
routine in our unit was not affected by its use. Never-
theless, pharmaco-economic studies are necessary to
validate the feasibility of the capsaicin patch. No im-
portant adverse events were gathered.
Competing interests
S.V. has received a fee for collaborating with Laboratorios Dr Esteve in pain
area. This work has not received funding. The authors declare that they have
no competing interests
Author’s contributions
MG-M, CB and SV designed and wrote the study protocol. MAN, AF, AO, AB and
LAM visited, monitored and followed up the patients, and applied the capsaicin
patch. MG-M, CH-C and SV performed the statistical analysis and updated the
database; all the authors participated in the analysis and interpretation of the
data. MG-M, CH-C and SV drafted the manuscript, and all the authors reviewed
it critically for important intellectual content. All the authors read and approved
the final version of the manuscript.
Acknowledgements
Special thanks also go to the patients from Pain Unit and the nursing team
M. Bellver and JL Gómez.
Author details
1Pain Unit, Department of Anesthesiology, Hospital Clínic de Barcelona,
Universitat de Barcelona, Carrer Villarroel 170, Barcelona 08036, Spain.
2Catalan Society of Pain, Barcelona, Spain. 3Department of Experimental and
Health Sciences. Faculty of Health and Life Sciences, Universitat Pompeu
Fabra, Barcelona, Spain.Received: 29 July 2013 Accepted: 11 December 2014
Published: 15 December 2014
References
1. Sindrup SH, Jensen TS: Efficacy of pharmacological treatments of
neuropathic pain: An update and effect related to mechanism of drug
action. Pain 1999, 83(3):389–400.
2. Jackson KC 2nd: Pharmacotherapy for neuropathic pain. Pain Pract 2006,
1:27–33.
3. Cruccu G, Aziz TZ, Garcia-Larrea L, Hansson P, Jensen TS, Lefaucheur JP,
Simpson BA, Taylor RS: EFNS guidelines on neurostimulation therapy for
neuropathic pain. Eur J Neurol 2007, 14(9):952–970.
4. Dworkin RH, O'Connor AB, Backonja M, Farrar JT, Finnerup NB, Jensen TS,
Kalso EA, Loeser JD, Miaskowski C, Nurmikko TJ, Portenoy RK, Rice AS,
Stacey BR, Treede RD, Turk DC, Wallace MS: Pharmacologic management
of neuropathic pain: Evidence-based recommendations. Pain 2007,
132(3):237–251.
5. Moulin DE, Clark AJ, Gilron I, Ware MA, Watson CP, Sessle BJ, Coderre T,
Morley-Forster PK, Stinson J, Boulanger A, Peng P, Finley GA, Taenzer P,
Squire P, Dion D, Cholkan A, Gilani A, Gordon A, Henry J, Jovey R, Lynch M,
Mailis-Gagnon A, Panju A, Rollman GB, Velly A: Pharmacological
management of chronic neuropathic pain - consensus statement and
guidelines from the canadian pain society. Pain Res Manag 2007,
12(1):13–21.
6. Attal N, Cruccu G, Baron R, Haanpää M, Hansson P, Jensen TS, Nurmikko T:
EFNS guidelines on the pharmacological treatment of neuropathic pain:
2010 revision. Eur J Neurol 2010, 17(9):1113-e88.
7. Anand P, Bley K: Topical capsaicin for pain management: Therapeutic
potential and mechanisms of action of the new high-concentration
capsaicin 8% patch. Br J Anaesth 2011, 107(4):490–502.
8. Qutenza. Summary of Product Characteristics. http://www.ema.europa.eu/
docs/es_ES/document_library/EPAR_-_Product_Information/human/000909/
WC500040453.pdf [accessed 16.12.14]
9. Armstrong EP, Malone DC, McCarberg B, Panarites CJ, Pham SV: Cost-
effectiveness analysis of a new 8% capsaicin patch compared to existing
therapies for postherpetic neuralgia. Curr Med Res Opin 2011, 27(5):939–950.
10. Darba J, Kaskens L, Perez-Alvarez N: Neuropathic pain: a budget impact
analysis to estimate costs due to the introduction of Qutenza® on the
Spanish market. Value Health 2011, 14:A411.
11. Clifford DB, Simpson DM, Brown S, Moyle G, Brew BJ, Conway B, Tobias JK,
Vanhove GF: A randomized, double-blind, controlled study of NGX-4010,
a capsaicin 8% dermal patch, for the treatment of painful HIV-associated
distal sensory polyneuropathy. J Acquir Immune Defic Syndr 2012,
59(2):126–133.
12. Webster LR, Peppin JF, Murphy FT, Lu B, Tobias JK, Vanhove GF: Efficacy,
safety, and tolerability of NGX-4010, capsaicin 8% patch, in an open-
label study of patients with peripheral neuropathic pain. Diabetes Res Clin
Pract 2011, 93(2):187–197.




14. Backonja M, Wallace MS, Blonsky ER, Cutler BJ, Malan P Jr, Rauck R, Tobias J:
NGX-4010, a high-concentration capsaicin patch, for the treatment of
postherpetic neuralgia: A randomised, double-blind study. Lancet Neurol
2008, 7(12):1106–1112.
15. Nolano M, Simone DA, Wendelschafer-Crabb G, Johnson T, Hazen E,
Kennedy WR: Topical capsaicin in humans: Parallel loss of epidermal
nerve fibers and pain sensation. Pain 1999, 81(1–2):135–145.
16. Caterina MJ, Julius D: The vanilloid receptor: A molecular gateway to the
pain pathway. Annu Rev Neurosci 2001, 24:487–517.
doi:10.1186/1471-2253-14-120
Cite this article as: Giménez-Milà et al.: Assessment of the feasibility of
high-concentration capsaicin patches in the pain unit of a tertiary
hospital for a population of mixed refractory peripheral neuropathic pain
syndromes in Non-diabetic patients. BMC Anesthesiology 2014 14:120.
